Prognostic Effect of Body Composition in Cancer Survivors

May 2, 2024 updated by: Lei Liu, West China Hospital

The Impact of DXA-Based Body Composition Phenotypes on the All-cause Mortality Among the US Cancer Survivors

This study aims to evaluate the association between body composition and mortality risk among the US population based on data from the National Health and Nutrition Examination Survey (NHANES), a nationally representative cohort.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

1500

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The data were extracted from National Health and Nutrition Examination Survey (NHANES) 1999 to 2006 and 2011 to 2018.

Description

Inclusion Criteria:

  • Participants with cancer diagnosis beyond 18 years old.

Exclusion Criteria:

  • Participants with missing cancer investigations and incomplete DXA body composition data were excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of all-cause mortality
Time Frame: Jan 1 1999 to Dec 31 2019
To evaluate the association between fat mass index (FMI, fat mass and height will be combined to report FMI in kg/m^2) and all-cause mortality among cancer survivors.
Jan 1 1999 to Dec 31 2019
Rate of all-cause mortality
Time Frame: Jan 1 1999 to Dec 31 2019
To evaluate the association between muscle mass index (MMI, muscle mass and height will be combined to report MMI in kg/m^2) and all-cause mortality among cancer survivors.
Jan 1 1999 to Dec 31 2019

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

West China Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 1999

Primary Completion (Actual)

December 31, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

April 24, 2024

First Submitted That Met QC Criteria

May 2, 2024

First Posted (Actual)

May 3, 2024

Study Record Updates

Last Update Posted (Actual)

May 3, 2024

Last Update Submitted That Met QC Criteria

May 2, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • #98-12, #2005-06, #2011-17

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Body Composition

Clinical Trials on body composition assessment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe